nodes	percent_of_prediction	percent_of_DWPC	metapath
Glipizide—CYP2C9—Vismodegib—skin cancer	0.146	0.236	CbGbCtD
Glipizide—CYP3A4—Temozolomide—skin cancer	0.123	0.198	CbGbCtD
Glipizide—CYP3A4—Imiquimod—skin cancer	0.123	0.198	CbGbCtD
Glipizide—CYP3A4—Vismodegib—skin cancer	0.0852	0.137	CbGbCtD
Glipizide—CYP3A4—Vemurafenib—skin cancer	0.0673	0.109	CbGbCtD
Glipizide—CYP2C9—Fluorouracil—skin cancer	0.052	0.0839	CbGbCtD
Glipizide—CYP3A4—Docetaxel—skin cancer	0.0231	0.0373	CbGbCtD
Glipizide—ABCC8—penis—skin cancer	0.0198	0.146	CbGeAlD
Glipizide—PPARG—dermis—skin cancer	0.0194	0.142	CbGeAlD
Glipizide—PPARG—leg—skin cancer	0.0128	0.094	CbGeAlD
Glipizide—PPARG—forelimb—skin cancer	0.0127	0.0933	CbGeAlD
Glipizide—PPARG—hindlimb—skin cancer	0.0114	0.0839	CbGeAlD
Glipizide—PPARG—appendage—skin cancer	0.00979	0.072	CbGeAlD
Glipizide—PPARG—endothelium—skin cancer	0.00591	0.0435	CbGeAlD
Glipizide—PPARG—blood vessel—skin cancer	0.00545	0.0401	CbGeAlD
Glipizide—PPARG—nipple—skin cancer	0.00394	0.029	CbGeAlD
Glipizide—PPARG—neck—skin cancer	0.0039	0.0287	CbGeAlD
Glipizide—KCNJ11—lymphoid tissue—skin cancer	0.00291	0.0214	CbGeAlD
Glipizide—KCNJ11—female reproductive system—skin cancer	0.0028	0.0206	CbGeAlD
Glipizide—PPARG—connective tissue—skin cancer	0.00279	0.0205	CbGeAlD
Glipizide—PPARG—epithelium—skin cancer	0.00265	0.0195	CbGeAlD
Glipizide—PPARG—skin of body—skin cancer	0.00252	0.0186	CbGeAlD
Glipizide—KCNJ11—head—skin cancer	0.00234	0.0172	CbGeAlD
Glipizide—PPARG—mammalian vulva—skin cancer	0.0023	0.0169	CbGeAlD
Glipizide—ABCC8—head—skin cancer	0.00216	0.0159	CbGeAlD
Glipizide—PPARG—lymphoid tissue—skin cancer	0.00204	0.015	CbGeAlD
Glipizide—PPARG—female reproductive system—skin cancer	0.00197	0.0145	CbGeAlD
Glipizide—PPARG—head—skin cancer	0.00165	0.0121	CbGeAlD
Glipizide—KCNJ11—lymph node—skin cancer	0.00164	0.0121	CbGeAlD
Glipizide—CYP2C9—female reproductive system—skin cancer	0.00115	0.00848	CbGeAlD
Glipizide—PPARG—lymph node—skin cancer	0.00115	0.00848	CbGeAlD
Glipizide—Nausea—Vismodegib—skin cancer	0.00108	0.00443	CcSEcCtD
Glipizide—Gastrointestinal haemorrhage—Fluorouracil—skin cancer	0.00108	0.00441	CcSEcCtD
Glipizide—Hepatocellular injury—Docetaxel—skin cancer	0.00107	0.00439	CcSEcCtD
Glipizide—Pancytopenia—Dactinomycin—skin cancer	0.00106	0.00435	CcSEcCtD
Glipizide—Malaise—Imiquimod—skin cancer	0.00106	0.00434	CcSEcCtD
Glipizide—Syncope—Imiquimod—skin cancer	0.00105	0.00432	CcSEcCtD
Glipizide—Loss of consciousness—Imiquimod—skin cancer	0.00103	0.00423	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.00102	0.0042	CcSEcCtD
Glipizide—Hypertension—Imiquimod—skin cancer	0.00101	0.00416	CcSEcCtD
Glipizide—Myalgia—Imiquimod—skin cancer	0.001	0.0041	CcSEcCtD
Glipizide—Arthralgia—Imiquimod—skin cancer	0.001	0.0041	CcSEcCtD
Glipizide—Anxiety—Imiquimod—skin cancer	0.000997	0.00408	CcSEcCtD
Glipizide—Discomfort—Imiquimod—skin cancer	0.000988	0.00405	CcSEcCtD
Glipizide—Decreased appetite—Vemurafenib—skin cancer	0.000977	0.004	CcSEcCtD
Glipizide—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000971	0.00398	CcSEcCtD
Glipizide—Constipation—Vemurafenib—skin cancer	0.000962	0.00394	CcSEcCtD
Glipizide—Pancytopenia—Temozolomide—skin cancer	0.00096	0.00393	CcSEcCtD
Glipizide—Oedema—Imiquimod—skin cancer	0.000959	0.00393	CcSEcCtD
Glipizide—Hypoaesthesia—Bleomycin—skin cancer	0.000954	0.00391	CcSEcCtD
Glipizide—Dysuria—Temozolomide—skin cancer	0.000945	0.00387	CcSEcCtD
Glipizide—Shock—Imiquimod—skin cancer	0.000943	0.00386	CcSEcCtD
Glipizide—Agranulocytosis—Dactinomycin—skin cancer	0.00093	0.00381	CcSEcCtD
Glipizide—Hyperhidrosis—Imiquimod—skin cancer	0.000927	0.0038	CcSEcCtD
Glipizide—Photosensitivity reaction—Temozolomide—skin cancer	0.000922	0.00378	CcSEcCtD
Glipizide—Anorexia—Imiquimod—skin cancer	0.000914	0.00374	CcSEcCtD
Glipizide—Hepatitis—Dactinomycin—skin cancer	0.000894	0.00366	CcSEcCtD
Glipizide—Flushing—Bleomycin—skin cancer	0.00089	0.00365	CcSEcCtD
Glipizide—Pharyngitis—Dactinomycin—skin cancer	0.000888	0.00364	CcSEcCtD
Glipizide—Pancytopenia—Fluorouracil—skin cancer	0.000884	0.00362	CcSEcCtD
Glipizide—CYP3A4—female reproductive system—skin cancer	0.00088	0.00647	CbGeAlD
Glipizide—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000874	0.00358	CcSEcCtD
Glipizide—Insomnia—Imiquimod—skin cancer	0.000867	0.00355	CcSEcCtD
Glipizide—Paraesthesia—Imiquimod—skin cancer	0.000861	0.00353	CcSEcCtD
Glipizide—Chills—Bleomycin—skin cancer	0.00086	0.00352	CcSEcCtD
Glipizide—Dyspnoea—Imiquimod—skin cancer	0.000855	0.0035	CcSEcCtD
Glipizide—Somnolence—Imiquimod—skin cancer	0.000852	0.00349	CcSEcCtD
Glipizide—Hepatobiliary disease—Temozolomide—skin cancer	0.000852	0.00349	CcSEcCtD
Glipizide—Photosensitivity reaction—Fluorouracil—skin cancer	0.00085	0.00348	CcSEcCtD
Glipizide—Dyspepsia—Imiquimod—skin cancer	0.000844	0.00346	CcSEcCtD
Glipizide—Erythema—Bleomycin—skin cancer	0.000835	0.00342	CcSEcCtD
Glipizide—Decreased appetite—Imiquimod—skin cancer	0.000834	0.00341	CcSEcCtD
Glipizide—Flushing—Dactinomycin—skin cancer	0.00083	0.0034	CcSEcCtD
Glipizide—Hypersensitivity—Vemurafenib—skin cancer	0.000828	0.00339	CcSEcCtD
Glipizide—Gastrointestinal disorder—Imiquimod—skin cancer	0.000828	0.00339	CcSEcCtD
Glipizide—Visual disturbance—Docetaxel—skin cancer	0.00082	0.00336	CcSEcCtD
Glipizide—Pain—Imiquimod—skin cancer	0.00082	0.00336	CcSEcCtD
Glipizide—Hepatitis—Temozolomide—skin cancer	0.000809	0.00331	CcSEcCtD
Glipizide—Conjunctivitis—Fluorouracil—skin cancer	0.000807	0.00331	CcSEcCtD
Glipizide—Asthenia—Vemurafenib—skin cancer	0.000807	0.0033	CcSEcCtD
Glipizide—Hypoaesthesia—Temozolomide—skin cancer	0.000805	0.0033	CcSEcCtD
Glipizide—Pharyngitis—Temozolomide—skin cancer	0.000803	0.00329	CcSEcCtD
Glipizide—Chills—Dactinomycin—skin cancer	0.000802	0.00329	CcSEcCtD
Glipizide—Pruritus—Vemurafenib—skin cancer	0.000796	0.00326	CcSEcCtD
Glipizide—Feeling abnormal—Imiquimod—skin cancer	0.00079	0.00324	CcSEcCtD
Glipizide—Gastrointestinal pain—Imiquimod—skin cancer	0.000784	0.00321	CcSEcCtD
Glipizide—Hyponatraemia—Docetaxel—skin cancer	0.000781	0.0032	CcSEcCtD
Glipizide—Visual impairment—Temozolomide—skin cancer	0.000779	0.00319	CcSEcCtD
Glipizide—Erythema—Dactinomycin—skin cancer	0.000778	0.00319	CcSEcCtD
Glipizide—Gastrointestinal haemorrhage—Docetaxel—skin cancer	0.000778	0.00319	CcSEcCtD
Glipizide—Agranulocytosis—Fluorouracil—skin cancer	0.000775	0.00317	CcSEcCtD
Glipizide—Ill-defined disorder—Bleomycin—skin cancer	0.000774	0.00317	CcSEcCtD
Glipizide—Diarrhoea—Vemurafenib—skin cancer	0.000769	0.00315	CcSEcCtD
Glipizide—Migraine—Docetaxel—skin cancer	0.000765	0.00314	CcSEcCtD
Glipizide—Urticaria—Imiquimod—skin cancer	0.000762	0.00312	CcSEcCtD
Glipizide—Abdominal pain—Imiquimod—skin cancer	0.000758	0.00311	CcSEcCtD
Glipizide—Eye disorder—Temozolomide—skin cancer	0.000756	0.0031	CcSEcCtD
Glipizide—Malaise—Bleomycin—skin cancer	0.000753	0.00308	CcSEcCtD
Glipizide—Flushing—Temozolomide—skin cancer	0.000751	0.00308	CcSEcCtD
Glipizide—Leukopenia—Bleomycin—skin cancer	0.000747	0.00306	CcSEcCtD
Glipizide—Rhinitis—Fluorouracil—skin cancer	0.000747	0.00306	CcSEcCtD
Glipizide—Dizziness—Vemurafenib—skin cancer	0.000744	0.00305	CcSEcCtD
Glipizide—Hypoaesthesia—Fluorouracil—skin cancer	0.000742	0.00304	CcSEcCtD
Glipizide—Pharyngitis—Fluorouracil—skin cancer	0.00074	0.00303	CcSEcCtD
Glipizide—Chills—Temozolomide—skin cancer	0.000726	0.00297	CcSEcCtD
Glipizide—Ill-defined disorder—Dactinomycin—skin cancer	0.000722	0.00296	CcSEcCtD
Glipizide—Vomiting—Vemurafenib—skin cancer	0.000715	0.00293	CcSEcCtD
Glipizide—Myalgia—Bleomycin—skin cancer	0.000711	0.00291	CcSEcCtD
Glipizide—Abdominal pain upper—Docetaxel—skin cancer	0.00071	0.00291	CcSEcCtD
Glipizide—Rash—Vemurafenib—skin cancer	0.000709	0.0029	CcSEcCtD
Glipizide—Dermatitis—Vemurafenib—skin cancer	0.000708	0.0029	CcSEcCtD
Glipizide—Hypersensitivity—Imiquimod—skin cancer	0.000706	0.00289	CcSEcCtD
Glipizide—Headache—Vemurafenib—skin cancer	0.000704	0.00289	CcSEcCtD
Glipizide—Erythema—Temozolomide—skin cancer	0.000704	0.00288	CcSEcCtD
Glipizide—Discomfort—Bleomycin—skin cancer	0.000702	0.00288	CcSEcCtD
Glipizide—Malaise—Dactinomycin—skin cancer	0.000702	0.00288	CcSEcCtD
Glipizide—Leukopenia—Dactinomycin—skin cancer	0.000697	0.00285	CcSEcCtD
Glipizide—Asthenia—Imiquimod—skin cancer	0.000688	0.00282	CcSEcCtD
Glipizide—Confusional state—Bleomycin—skin cancer	0.000687	0.00281	CcSEcCtD
Glipizide—Oedema—Bleomycin—skin cancer	0.000681	0.00279	CcSEcCtD
Glipizide—Pruritus—Imiquimod—skin cancer	0.000678	0.00278	CcSEcCtD
Glipizide—Nausea—Vemurafenib—skin cancer	0.000668	0.00274	CcSEcCtD
Glipizide—Thrombocytopenia—Bleomycin—skin cancer	0.000667	0.00273	CcSEcCtD
Glipizide—Arrhythmia—Fluorouracil—skin cancer	0.000666	0.00273	CcSEcCtD
Glipizide—Vision blurred—Temozolomide—skin cancer	0.000664	0.00272	CcSEcCtD
Glipizide—Myalgia—Dactinomycin—skin cancer	0.000663	0.00272	CcSEcCtD
Glipizide—Tremor—Temozolomide—skin cancer	0.00066	0.0027	CcSEcCtD
Glipizide—Diarrhoea—Imiquimod—skin cancer	0.000656	0.00269	CcSEcCtD
Glipizide—Discomfort—Dactinomycin—skin cancer	0.000655	0.00268	CcSEcCtD
Glipizide—Ill-defined disorder—Temozolomide—skin cancer	0.000653	0.00268	CcSEcCtD
Glipizide—Anorexia—Bleomycin—skin cancer	0.000649	0.00266	CcSEcCtD
Glipizide—Erythema—Fluorouracil—skin cancer	0.000649	0.00266	CcSEcCtD
Glipizide—Pancytopenia—Docetaxel—skin cancer	0.000638	0.00261	CcSEcCtD
Glipizide—Oedema—Dactinomycin—skin cancer	0.000635	0.0026	CcSEcCtD
Glipizide—Malaise—Temozolomide—skin cancer	0.000635	0.0026	CcSEcCtD
Glipizide—Dizziness—Imiquimod—skin cancer	0.000634	0.0026	CcSEcCtD
Glipizide—Vertigo—Temozolomide—skin cancer	0.000633	0.00259	CcSEcCtD
Glipizide—Leukopenia—Temozolomide—skin cancer	0.00063	0.00258	CcSEcCtD
Glipizide—Thrombocytopenia—Dactinomycin—skin cancer	0.000622	0.00255	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000621	0.00254	CcSEcCtD
Glipizide—Paraesthesia—Bleomycin—skin cancer	0.000612	0.00251	CcSEcCtD
Glipizide—Vision blurred—Fluorouracil—skin cancer	0.000611	0.0025	CcSEcCtD
Glipizide—Vomiting—Imiquimod—skin cancer	0.00061	0.0025	CcSEcCtD
Glipizide—Hypertension—Temozolomide—skin cancer	0.000608	0.00249	CcSEcCtD
Glipizide—Dyspnoea—Bleomycin—skin cancer	0.000607	0.00249	CcSEcCtD
Glipizide—Anorexia—Dactinomycin—skin cancer	0.000606	0.00248	CcSEcCtD
Glipizide—Rash—Imiquimod—skin cancer	0.000605	0.00248	CcSEcCtD
Glipizide—Dermatitis—Imiquimod—skin cancer	0.000604	0.00247	CcSEcCtD
Glipizide—Headache—Imiquimod—skin cancer	0.000601	0.00246	CcSEcCtD
Glipizide—Arthralgia—Temozolomide—skin cancer	0.000599	0.00246	CcSEcCtD
Glipizide—Myalgia—Temozolomide—skin cancer	0.000599	0.00246	CcSEcCtD
Glipizide—Anxiety—Temozolomide—skin cancer	0.000597	0.00245	CcSEcCtD
Glipizide—Discomfort—Temozolomide—skin cancer	0.000592	0.00243	CcSEcCtD
Glipizide—Decreased appetite—Bleomycin—skin cancer	0.000592	0.00243	CcSEcCtD
Glipizide—Jaundice—Docetaxel—skin cancer	0.000584	0.00239	CcSEcCtD
Glipizide—Pain—Bleomycin—skin cancer	0.000583	0.00239	CcSEcCtD
Glipizide—Conjunctivitis—Docetaxel—skin cancer	0.000582	0.00239	CcSEcCtD
Glipizide—Leukopenia—Fluorouracil—skin cancer	0.000581	0.00238	CcSEcCtD
Glipizide—Confusional state—Temozolomide—skin cancer	0.000579	0.00237	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000579	0.00237	CcSEcCtD
Glipizide—Oedema—Temozolomide—skin cancer	0.000575	0.00235	CcSEcCtD
Glipizide—Nausea—Imiquimod—skin cancer	0.00057	0.00233	CcSEcCtD
Glipizide—Hepatobiliary disease—Docetaxel—skin cancer	0.000567	0.00232	CcSEcCtD
Glipizide—Thrombocytopenia—Temozolomide—skin cancer	0.000563	0.0023	CcSEcCtD
Glipizide—Feeling abnormal—Bleomycin—skin cancer	0.000561	0.0023	CcSEcCtD
Glipizide—Agranulocytosis—Docetaxel—skin cancer	0.000559	0.00229	CcSEcCtD
Glipizide—Hyperhidrosis—Temozolomide—skin cancer	0.000556	0.00228	CcSEcCtD
Glipizide—Myalgia—Fluorouracil—skin cancer	0.000552	0.00226	CcSEcCtD
Glipizide—Decreased appetite—Dactinomycin—skin cancer	0.000552	0.00226	CcSEcCtD
Glipizide—Anorexia—Temozolomide—skin cancer	0.000548	0.00224	CcSEcCtD
Glipizide—Discomfort—Fluorouracil—skin cancer	0.000546	0.00224	CcSEcCtD
Glipizide—Pain—Dactinomycin—skin cancer	0.000543	0.00223	CcSEcCtD
Glipizide—Urticaria—Bleomycin—skin cancer	0.000541	0.00222	CcSEcCtD
Glipizide—Rhinitis—Docetaxel—skin cancer	0.000539	0.00221	CcSEcCtD
Glipizide—Hepatitis—Docetaxel—skin cancer	0.000538	0.0022	CcSEcCtD
Glipizide—Hypoaesthesia—Docetaxel—skin cancer	0.000535	0.00219	CcSEcCtD
Glipizide—Confusional state—Fluorouracil—skin cancer	0.000534	0.00219	CcSEcCtD
Glipizide—Pharyngitis—Docetaxel—skin cancer	0.000534	0.00219	CcSEcCtD
Glipizide—Oedema—Fluorouracil—skin cancer	0.000529	0.00217	CcSEcCtD
Glipizide—Feeling abnormal—Dactinomycin—skin cancer	0.000524	0.00214	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000524	0.00214	CcSEcCtD
Glipizide—Insomnia—Temozolomide—skin cancer	0.00052	0.00213	CcSEcCtD
Glipizide—Gastrointestinal pain—Dactinomycin—skin cancer	0.00052	0.00213	CcSEcCtD
Glipizide—Thrombocytopenia—Fluorouracil—skin cancer	0.000518	0.00212	CcSEcCtD
Glipizide—Visual impairment—Docetaxel—skin cancer	0.000518	0.00212	CcSEcCtD
Glipizide—Paraesthesia—Temozolomide—skin cancer	0.000516	0.00211	CcSEcCtD
Glipizide—Dyspnoea—Temozolomide—skin cancer	0.000512	0.0021	CcSEcCtD
Glipizide—Somnolence—Temozolomide—skin cancer	0.000511	0.00209	CcSEcCtD
Glipizide—Dyspepsia—Temozolomide—skin cancer	0.000506	0.00207	CcSEcCtD
Glipizide—Anorexia—Fluorouracil—skin cancer	0.000505	0.00207	CcSEcCtD
Glipizide—Eye disorder—Docetaxel—skin cancer	0.000503	0.00206	CcSEcCtD
Glipizide—Abdominal pain—Dactinomycin—skin cancer	0.000502	0.00206	CcSEcCtD
Glipizide—Hypersensitivity—Bleomycin—skin cancer	0.000502	0.00206	CcSEcCtD
Glipizide—Decreased appetite—Temozolomide—skin cancer	0.0005	0.00205	CcSEcCtD
Glipizide—Flushing—Docetaxel—skin cancer	0.000499	0.00205	CcSEcCtD
Glipizide—Gastrointestinal disorder—Temozolomide—skin cancer	0.000496	0.00203	CcSEcCtD
Glipizide—Pain—Temozolomide—skin cancer	0.000491	0.00201	CcSEcCtD
Glipizide—Constipation—Temozolomide—skin cancer	0.000491	0.00201	CcSEcCtD
Glipizide—Asthenia—Bleomycin—skin cancer	0.000489	0.002	CcSEcCtD
Glipizide—Chills—Docetaxel—skin cancer	0.000483	0.00198	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000482	0.00198	CcSEcCtD
Glipizide—Pruritus—Bleomycin—skin cancer	0.000482	0.00197	CcSEcCtD
Glipizide—Arrhythmia—Docetaxel—skin cancer	0.000481	0.00197	CcSEcCtD
Glipizide—Insomnia—Fluorouracil—skin cancer	0.000479	0.00196	CcSEcCtD
Glipizide—Paraesthesia—Fluorouracil—skin cancer	0.000475	0.00195	CcSEcCtD
Glipizide—Feeling abnormal—Temozolomide—skin cancer	0.000474	0.00194	CcSEcCtD
Glipizide—Dyspnoea—Fluorouracil—skin cancer	0.000472	0.00193	CcSEcCtD
Glipizide—Somnolence—Fluorouracil—skin cancer	0.000471	0.00193	CcSEcCtD
Glipizide—Gastrointestinal pain—Temozolomide—skin cancer	0.00047	0.00192	CcSEcCtD
Glipizide—Erythema—Docetaxel—skin cancer	0.000468	0.00192	CcSEcCtD
Glipizide—Hypersensitivity—Dactinomycin—skin cancer	0.000468	0.00192	CcSEcCtD
Glipizide—Dyspepsia—Fluorouracil—skin cancer	0.000466	0.00191	CcSEcCtD
Glipizide—Decreased appetite—Fluorouracil—skin cancer	0.00046	0.00189	CcSEcCtD
Glipizide—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000457	0.00187	CcSEcCtD
Glipizide—Urticaria—Temozolomide—skin cancer	0.000457	0.00187	CcSEcCtD
Glipizide—Asthenia—Dactinomycin—skin cancer	0.000456	0.00187	CcSEcCtD
Glipizide—Abdominal pain—Temozolomide—skin cancer	0.000454	0.00186	CcSEcCtD
Glipizide—Pain—Fluorouracil—skin cancer	0.000453	0.00185	CcSEcCtD
Glipizide—Muscle spasms—Docetaxel—skin cancer	0.00045	0.00184	CcSEcCtD
Glipizide—Feeling abnormal—Fluorouracil—skin cancer	0.000436	0.00179	CcSEcCtD
Glipizide—Diarrhoea—Dactinomycin—skin cancer	0.000435	0.00178	CcSEcCtD
Glipizide—Vomiting—Bleomycin—skin cancer	0.000433	0.00177	CcSEcCtD
Glipizide—Rash—Bleomycin—skin cancer	0.00043	0.00176	CcSEcCtD
Glipizide—Dermatitis—Bleomycin—skin cancer	0.000429	0.00176	CcSEcCtD
Glipizide—Hypersensitivity—Temozolomide—skin cancer	0.000423	0.00173	CcSEcCtD
Glipizide—Urticaria—Fluorouracil—skin cancer	0.000421	0.00172	CcSEcCtD
Glipizide—Syncope—Docetaxel—skin cancer	0.00042	0.00172	CcSEcCtD
Glipizide—Leukopenia—Docetaxel—skin cancer	0.000419	0.00172	CcSEcCtD
Glipizide—Asthenia—Temozolomide—skin cancer	0.000412	0.00169	CcSEcCtD
Glipizide—Loss of consciousness—Docetaxel—skin cancer	0.000412	0.00169	CcSEcCtD
Glipizide—Pruritus—Temozolomide—skin cancer	0.000407	0.00167	CcSEcCtD
Glipizide—Nausea—Bleomycin—skin cancer	0.000405	0.00166	CcSEcCtD
Glipizide—Hypertension—Docetaxel—skin cancer	0.000404	0.00166	CcSEcCtD
Glipizide—Vomiting—Dactinomycin—skin cancer	0.000404	0.00165	CcSEcCtD
Glipizide—Rash—Dactinomycin—skin cancer	0.000401	0.00164	CcSEcCtD
Glipizide—Arthralgia—Docetaxel—skin cancer	0.000399	0.00163	CcSEcCtD
Glipizide—Myalgia—Docetaxel—skin cancer	0.000399	0.00163	CcSEcCtD
Glipizide—Diarrhoea—Temozolomide—skin cancer	0.000393	0.00161	CcSEcCtD
Glipizide—Hypersensitivity—Fluorouracil—skin cancer	0.00039	0.0016	CcSEcCtD
Glipizide—Confusional state—Docetaxel—skin cancer	0.000385	0.00158	CcSEcCtD
Glipizide—Oedema—Docetaxel—skin cancer	0.000382	0.00157	CcSEcCtD
Glipizide—Dizziness—Temozolomide—skin cancer	0.00038	0.00156	CcSEcCtD
Glipizide—Nausea—Dactinomycin—skin cancer	0.000377	0.00155	CcSEcCtD
Glipizide—Shock—Docetaxel—skin cancer	0.000376	0.00154	CcSEcCtD
Glipizide—Pruritus—Fluorouracil—skin cancer	0.000375	0.00153	CcSEcCtD
Glipizide—Thrombocytopenia—Docetaxel—skin cancer	0.000374	0.00153	CcSEcCtD
Glipizide—Vomiting—Temozolomide—skin cancer	0.000365	0.0015	CcSEcCtD
Glipizide—Anorexia—Docetaxel—skin cancer	0.000364	0.00149	CcSEcCtD
Glipizide—Rash—Temozolomide—skin cancer	0.000362	0.00148	CcSEcCtD
Glipizide—Diarrhoea—Fluorouracil—skin cancer	0.000362	0.00148	CcSEcCtD
Glipizide—Dermatitis—Temozolomide—skin cancer	0.000362	0.00148	CcSEcCtD
Glipizide—Headache—Temozolomide—skin cancer	0.00036	0.00147	CcSEcCtD
Glipizide—Dizziness—Fluorouracil—skin cancer	0.00035	0.00143	CcSEcCtD
Glipizide—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000348	0.00143	CcSEcCtD
Glipizide—Insomnia—Docetaxel—skin cancer	0.000346	0.00142	CcSEcCtD
Glipizide—Paraesthesia—Docetaxel—skin cancer	0.000343	0.00141	CcSEcCtD
Glipizide—Nausea—Temozolomide—skin cancer	0.000341	0.0014	CcSEcCtD
Glipizide—Dyspnoea—Docetaxel—skin cancer	0.000341	0.0014	CcSEcCtD
Glipizide—Somnolence—Docetaxel—skin cancer	0.00034	0.00139	CcSEcCtD
Glipizide—Vomiting—Fluorouracil—skin cancer	0.000337	0.00138	CcSEcCtD
Glipizide—Dyspepsia—Docetaxel—skin cancer	0.000336	0.00138	CcSEcCtD
Glipizide—Rash—Fluorouracil—skin cancer	0.000334	0.00137	CcSEcCtD
Glipizide—Dermatitis—Fluorouracil—skin cancer	0.000334	0.00137	CcSEcCtD
Glipizide—Decreased appetite—Docetaxel—skin cancer	0.000332	0.00136	CcSEcCtD
Glipizide—Headache—Fluorouracil—skin cancer	0.000332	0.00136	CcSEcCtD
Glipizide—Gastrointestinal disorder—Docetaxel—skin cancer	0.00033	0.00135	CcSEcCtD
Glipizide—Constipation—Docetaxel—skin cancer	0.000327	0.00134	CcSEcCtD
Glipizide—Pain—Docetaxel—skin cancer	0.000327	0.00134	CcSEcCtD
Glipizide—Feeling abnormal—Docetaxel—skin cancer	0.000315	0.00129	CcSEcCtD
Glipizide—Nausea—Fluorouracil—skin cancer	0.000314	0.00129	CcSEcCtD
Glipizide—Gastrointestinal pain—Docetaxel—skin cancer	0.000312	0.00128	CcSEcCtD
Glipizide—Abdominal pain—Docetaxel—skin cancer	0.000302	0.00124	CcSEcCtD
Glipizide—Hypersensitivity—Docetaxel—skin cancer	0.000282	0.00115	CcSEcCtD
Glipizide—Asthenia—Docetaxel—skin cancer	0.000274	0.00112	CcSEcCtD
Glipizide—Pruritus—Docetaxel—skin cancer	0.00027	0.00111	CcSEcCtD
Glipizide—Diarrhoea—Docetaxel—skin cancer	0.000261	0.00107	CcSEcCtD
Glipizide—Dizziness—Docetaxel—skin cancer	0.000253	0.00104	CcSEcCtD
Glipizide—Vomiting—Docetaxel—skin cancer	0.000243	0.000995	CcSEcCtD
Glipizide—Rash—Docetaxel—skin cancer	0.000241	0.000987	CcSEcCtD
Glipizide—Dermatitis—Docetaxel—skin cancer	0.000241	0.000986	CcSEcCtD
Glipizide—Headache—Docetaxel—skin cancer	0.000239	0.000981	CcSEcCtD
Glipizide—Nausea—Docetaxel—skin cancer	0.000227	0.00093	CcSEcCtD
